Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir

Table 2

Serum NGAL among the patients when ranked by different parameters.

Parameter	(No., %)	Serum NGAL (ng/ml)	value
Gender
Male	26 (29.9%)	336.69 ± 217.31	0.75
Female	61 (70.1%)	330.92 ± 333.69
Diabetes
Yes	6 (6.9%)	265.73 ± 60.40	0.39
No	81 (93.1%)	337.60 ± 312.55
Hypertension
Yes	18 (20.7%)	362.4 ± 279.77	0.35
No	69 (79.3%)	324.88 ± 309.44
Liver
Normal	60 (69%)	327.19 ± 221.00	0.65
Cirrhotic	27 (31%)	344.78 ± 437.42
HCV RNA (copies/ml)
Less than 1000000	51 (58.6%)	336.57 ± 356.83	0.58
More than 1000000	36 (41.4%)	327.09 ± 206.59
FIB4
G1: <1.45	41 (47.1%)	329.99 ± 368.24
G2: 1.45 to 3.25	42 (38. 3%)	346.56 ± 240.549
G3: >3.25	4 (4.6%)	213.8 ± 15.05
APRI
G1: <0.5	45 (51.7%)	329.99 ± 368.24
G2: 0.5–1.5	38 (43.7%)	346.56 ± 240.55
G3: >1.5	4 (4.6%)	213.8 ± 15.05

G: group; : value for G1 vs G2; : value for G1 vs G3; : value for G2 vs G3.